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Abstract
Schistosomes have a well developed nervous system that coordinates virtually every activity of the parasite and therefore is
considered to be a promising target for chemotherapeutic intervention. Neurotransmitter receptors, in particular those
involved in neuromuscular control, are proven drug targets in other helminths but very few of these receptors have been
identified in schistosomes and little is known about their roles in the biology of the worm. Here we describe a novel
Schistosoma mansoni G protein-coupled receptor (named SmGPR-3) that was cloned, expressed heterologously and shown
to be activated by dopamine, a well established neurotransmitter of the schistosome nervous system. SmGPR-3 belongs to a
new clade of ‘‘orphan’’ amine-like receptors that exist in schistosomes but not the mammalian host. Further analysis of the
recombinant protein showed that SmGPR-3 can also be activated by other catecholamines, including the dopamine
metabolite, epinine, and it has an unusual antagonist profile when compared to mammalian receptors. Confocal
immunofluorescence experiments using a specific peptide antibody showed that SmGPR-3 is abundantly expressed in the
nervous system of schistosomes, particularly in the main nerve cords and the peripheral innervation of the body wall
muscles. In addition, we show that dopamine, epinine and other dopaminergic agents have strong effects on the motility of
larval schistosomes in culture. Together, the results suggest that SmGPR-3 is an important neuronal receptor and is
probably involved in the control of motor activity in schistosomes. We have conducted a first analysis of the structure of
SmGPR-3 by means of homology modeling and virtual ligand-docking simulations. This investigation has identified
potentially important differences between SmGPR-3 and host dopamine receptors that could be exploited to develop new,
parasite-selective anti-schistosomal drugs.
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Introduction
The bloodfluke Schistosoma mansoni is one of three species of
schistosomes that cause significant disease in humans. Approxi-
mately 200 million people are infected and another 600 million are
at risk of infection. Over 90% of all human schistosomiasis is due
to S. mansoni. This species exists in Africa, the Middle East, South
America and the Caribbean, in regions where the intermediate
snail host, Biomphalaria glabrata, is also present. There is no vaccine
for schistosomiasis and the arsenal of drugs available for treatment
is limited. Praziquantel is the drug of choice but concerns over
praziquantel resistance [1–3] have renewed interest in the search
for alternative drug therapies. The nervous system of helminth
parasites is considered to be an excellent target for chemothera-
peutic intervention. Most of the anthelmintics currently in use,
including the mainstay of nematode control, ivermectin, act by
interacting with neurotransmitter receptors and cause disruption
of neuronal signalling [4]. Recent drug screens conducted on
cultured S. mansoni suggest that biogenic amine (BA) neurotrans-
mitters may be particularly suitable for development of anti-
schistosomal drugs [5,6]. Substances that normally disrupt BA
neurotransmission, such as dopaminergic and serotonergic drugs
were shown to halt larval development [5] and to produce
aberrant motor phenotypes in culture [6]. The BA systems of
schistosomes have not been widely investigated at the molecular
level and not much is known about the receptors or other proteins
involved. More information is needed to elucidate the mode of
action of these neurotransmitters and to identify potential targets
for drug discovery.
BAs constitute a group of structurally related amino acid
derivatives that function broadly as neurotransmitters and
modulators in a variety of organisms. Included in this group are
catecholamines (dopamine, noradrenaline, adrenaline), serotonin
(5-hydroxytryptamine: 5-HT), histamine and the invertebrate-
specific amines, tyramine and octopamine. In flatworms, including
S. mansoni, BAs play important roles in the control of muscle
contraction and movement, activities that are crucial for survival
of the parasite within the host [7–9]. The best characterized of
these amines is serotonin, which is myoexcitatory in all the
flatworm species studied to date. Serotonin is synthesized by the
parasite [10], it is widely distributed in the nervous system and
there is evidence for the existence of a serotonin transport system
www.plosntds.org 1 February 2012 | Volume 6 | Issue 2 | e1523in S. mansoni [11,12]. At least two putative serotonin receptors
are encoded in the S. mansoni genome [13], though neither has
yet been characterized at the protein level. Besides serotonin,
flatworms have both dopamine and histamine within their nervous
system [14–20]. Dopamine, in particular, has important neuro-
muscular activities, which can be either excitatory or inhibitory
depending on the flatworm species. In S. mansoni, dopamine causes
relaxation of the body wall muscles [21], possibly by activating a
receptor that is associated with neuromuscular structures [22].
In addition to motor effects, BAs have been implicated in the
regulation of metabolic activity in several flatworms [8] and
recent evidence has shown that serotonin and dopamine are
both involved in the transformation of S. mansoni miracidia
to sporocyst stage [5], suggesting a probable role in parasite
development.
BAs exert their effects by interacting with cell-surface receptors,
the majority of which belong to the superfamily of G protein-
coupled receptors (GPCR) and are structurally related to
rhodopsin. GPCRs have a distinctive topology consisting of seven
transmembrane (TM) domains separated by loops, the longest of
which is the third intracellular loop (il3). Rhodopsin-like (or Class
A) GPCRs are further identified by having a relatively short
extracelullar N-terminus, which is typically glycosylated, and an
intracellular C-terminal tail of variable length [23]. In mammals,
BA receptors are classified according to their amine specificity,
sequence homology, signalling mechanisms and pharmacological
profiles. Each BA interacts with multiple receptors. Dopamine, in
particular, interacts with five different receptors (D1–D5), which
are classified according to two major structural types, D1- and D2-
like [24]. The current annotation of the S. mansoni genome has a
total of 16 predicted BA receptors, all Class A GPCRs [13]. A few
of these sequences, for example the D2-like dopamine receptor of
S. mansoni (SmD2) [22] share sufficient homology with mammalian
prototypes to be classified accordingly. The majority, however, are
novel sequences that share about the same level of homology with
all different types of BA receptors and can only be defined as BA-
like. Among these sequences is a new clade of BA-like GPCRs
(named SmGPR) that were previously described in our laboratory
[15] and thus far have been detected only in schistosomes. These
receptors could prove to be particularly good candidates for
selective drug targeting and deserve further investigation.
Two SmGPRs of S. mansoni were shown earlier to be functional
histamine receptors [15,25–27]. Here we describe a third stru-
cturally related receptor (SmGPR-3), which has different agonist
specificity. The results presented here show that SmGPR-3 is
activated by dopamine and other catecholamines but does not
resemble any one particular type of host dopamine receptor, either
in terms of overall sequence homology, pharmacological profile or
the predicted organization of the binding pocket. Further analysis
of the receptor’s tissue distribution revealed exceptionally
abundant expression throughout the nervous system and suggests
an important role for this novel dopamine receptor in neuronal
and neuromuscular signalling.
Materials and Methods
Parasites
A Puerto Rican strain of S. mansoni -infected Biomphalaria glabrata
snails were kindly provided by Dr. Fred Lewis, Biomedical
Research Institute, Rockville, Maryland, USA. S. mansoni cercaria
were collected from infected snails 35–45 days post-infection.
Schistosomula were produced from cercaria by mechanical
transformation, as described [27,28] and were cultured at 37uC
and 5% CO2 in OPTI-MEM I medium (Invitrogen) supplemented
with 10% FBS, streptomycin 100 mg/ml, penicillin 100 U/ml and
fungizone 0.25 mg/ml. Adult parasites were obtained by infecting
28-day old female CD-1 mice with freshly collected cercaria (150
cercaria/animal) by skin penetration. Adult S. mansoni worms were
recovered 7 weeks post-infection by perfusion of the liver [28],
washed extensively and either flash-frozen in liquid nitrogen for
subsequent RNA extraction or fixed in 4% paraformaldehyde
(PFA) for immunolocalization experiments. Animal procedures
were reviewed and approved by the Facility Animal Care
Committee of McGill University (Protocol No. 3346) and were
conducted in accordance with the guidelines of the Canadian
Council on Animal Care.
Cloning of SmGPR-3
The full-length SmGPR-3 cDNA was cloned from adult S. mansoni
based on a predicted coding sequence (Smp_043290) obtained from
the S. mansoni genome database (S. mansoni GeneDB; http://www.
genedb.org/Homepage/Smansoni). Total RNA was purified from
adult S.mansoniworms (Qiagen RNeasykit) and was oligo-dT reverse-
transcribed with MMLV reverse transcriptase (Invitrogen), according
to standard procedures. SmGPR-3 was cloned with primers that
targeted the beginning and end of the predicted coding sequence.
The primer sequences were as follows: 59-ATGAATTTCATAA-
GAAACAAAACCAATTATTC-39 (sense) and 59-CTATCTA-
CATCCTTTCAAAAGTACAATATG-39 (antisense). A proofread-
ing Platinum Pfx DNA polymerase (Invitrogen) was used to amplify
the cDNA in a standard PCR reaction (35 cycles of 94uC/15 s,
53.1uC/30 s and 68uC/90 s). The resulting amplicon (1,494 bp) was
ligated to pGEM-T Easy vector (Promega) and verified by DNA
sequencing of two independent clones.
Yeast functional expression assays
The SmGPR-3 coding sequence was sub-cloned between the
NcoI/XbaI restriction sites of the yeast expression vector Cp4258
(kindly provided by Dr J. Broach, Princeton University, NJ, USA).
The functional expression assay was adapted from the protocol of
Wang and colleagues [29] as described [15,30]. The receptor was
expressed in Saccharomyces cerevisiae strain YEX108 (MATa PFUS1-
Author Summary
Bloodflukes of the genus Schistosoma are the causative
agents of human schistosomiasis, a debilitating disease
that afflicts over 200 million people worldwide. There is no
vaccine for schistosomiasis and treatment relies heavily on
a single drug, praziquantel. Recent reports of praziquantel
resistance raise concerns about future control of the
disease and show the importance of developing new anti-
schistosomal drugs. The focus of this research is on the
nervous system of the model fluke, Schistosoma mansoni.
Many pesticides and antiparasitic drugs act by interacting
with neuronal proteins and therefore the nervous system
is a particularly attractive target for chemotherapeutic
intervention. Here we describe a novel receptor of S.
mansoni that is activated by dopamine, an important
neurotransmitter of the schistosome nervous system. The
study provides a first in-depth analysis of this receptor and
suggests that it plays an important role in the control of
muscle function and movement. We also show that the
schistosome receptor is substantially different from
dopamine receptors of the mammalian host, both in
terms of structure and functional properties. We propose
that this novel protein could be used to develop new,
schistosome-specific drugs aimed at disrupting parasite
motility within the host.
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sst2D2 ste14::trp1::LYS2 ste18D6-3841 ste3D1156 tbt1-1 trp1 ura3;
kindly provided by J. Broach, Princeton University, NJ, USA).
This strain expresses the HIS3 reporter gene under the control of
the FUS1 promoter and contains an integrated copy of a chimeric
Ga gene in which the first 31 and last five codons of native
yeast Ga (GPA1) were replaced with those of human Gaq [29].
Other strains carrying chimeras of GPA1 and human Gai2,G a12,
Gao or Gas were tested in preliminary experiments but were
found to yield lower or no receptor activity compared with strain
YEX108. YPD culture medium (1% yeast extract, 2% peptone
and 2% dextrose) was used to culture YEX108 strain, according to
standard conditions. The lithium acetate method was performed
to transform yeast with either empty Cp4258 vector (mock) or
Cp4258/SmGPR-3 expression plasmid, using 200 ml mid-log
phase cells, 200 mg carrier single stranded DNA (Invitrogen) and
1 mg plasmid. Positive transformants were selected on synthetic
complete (SC) 2% glucose solid medium lacking leucine (SC/
leu
2). For agonist assays, single colonies of transformants were
cultured overnight in SC/leu
2 liquid medium at 250 rpm/30uC.
The next day, cells were washed four times in SC 2% glucose
liquid medium that lacked both leucine and histidine (SC/leu
2/
his
2). Cells were finally resuspended in SC/leu
2/his
2 medium
supplemented with 50 mM 3-(N-morpholino) propanesulfonic
acid (MOPS), pH 6.8 and 1.5 mM 3-Amino-1, 2, 4-Triazole
(3-AT). The latter was used to reduce basal growth due to
endogenous background signalling as it inhibits the gene product
of HIS3 [29]. Aliquots containing approximately 3,000 cells were
added to individual wells of a 96-well plate containing test agonist
or vehicle plus additional medium for a total reaction volume of
100 ml. The plates were incubated at 30uC for 22–26 h, after
which 10 ml of Alamar blue (Invitrogen) was added to each well.
The plates were returned to the 30uC incubator until the Alamar
blue color started to shift to pink (approximately 1–4 h) and
fluorescence (560 nm excitation/590 nm emission) was measured
at 30uC every hour up to three hours, using a plate fluorometer
(FlexStation II, Molecular Devices, US). Antagonist assays were
done in a similar way, except that each well contained 10
24 M
agonist (dopamine) and the antagonist at the specified concentra-
tion. Data analyses and dose-response curve fits were performed
using Prism v5.0 (GraphPad software Inc.).
SmGPR-3 antibody production
Polyclonal antibodies were produced in rabbits against two
SmGPR-3 synthetic peptides. The first peptide (CYISYSKEYR-
IYSSV) is located in the predicted 2
nd extracellular loop (ECL2) of
SmGPR-3 (positions 186–200) and the second peptide sequence
(CERKTERTIKTQRQF) is in the third intracellular loop (il3)
(positions 395–409). The two peptide sequences were tested
against the S. mansoni GeneDB database and the general database
at The National Center for Biotechnology Information (NCBI)
to insure specificity. The peptides were both conjugated to
ovalbumin to increase immunogenicity. The conjugated peptides
and custom antibodies were purchased from 21
st Century
Biochemicals, Malboro, MA, USA. Antibodies were raised in
two rabbits, each of which was inoculated five times and the serum
was collected prior to injection (preimmune) and up to 72 days
following injection (see http://21stcenturybio.com/ for further
details of the antibody protocol). ELISA was done to test the
specificity of the antibodies to each of the two peptides. SmGPR-3
–specific antibodies were subsequently affinity-purified, using the
MicroLink Peptide Coupling kit (Pierce), as described previously
[22].
Immunoprecipitation and western blotting
Immunoprecipitation (IP) was performed with the Seize
Primary Immunoprecipitation kit (Pierce, USA), as described
previously [22]. Briefly, IP affinity columns were prepared by
covalent coupling of purified anti-SmGPR-3 IgG to AminoLink
Plus gel in the presence of sodium cyanoborohydride. A solubilized
membrane fraction was prepared from adult S. mansoni, using a
commercial kit (ProteoExtract Native Membrane Protein Extrac-
tion Kit, Calbiochem) and aliquots of solubilized membrane
proteins (14 mg protein) were mixed with 50 ml IgG-linked gel and
incubated overnight at 4uC with gentle rotation. After incubation,
the gel was washed extensively and the bound proteins were eluted
under acidic conditions, using the elution buffer supplied by the
kit. The immunoprecipitated proteins were resolved on 4–12%
Tris-Glycine precast gel (Invitrogen) and transferred to polyviny-
lidene fluoride (PVDF) membranes (Millipore). Western blot
analysis was performed according to standard protocols, using
purified anti-SmGPR-3 antibody (dilution 1/10,000) and a goat
anti-rabbit Horseradish Peroxidase (HRP)-conjugated antibody
(Calbiochem) (1/20, 000). To test for specificity, the western blots
were repeated with primary antibody that was preadsorbed with
0.5 mg/ml of pooled peptide antigens (0.25 mg of each peptide) or
preimmune serum.
Confocal immunofluorescence
The procedure is based on the protocol of D. Halton and
colleagues [31], as described previously [22,27]. S. mansoni cercaria
and adult worms were fixed in 4% paraformaldehyde (PFA) for
4 h at 4uC, washed three times in blocking buffer (16 PBS,
pH 7.4; 1% bovine serum albumin; 0.1% sodium azide and 0.5%
triton X-100) and were incubated in 10 mM sodium citrate for 1 h
at 70uC. Animals were subsequently washed twice with PBS,
incubated with affinity-purified anti-SmGPR-3 antibody (diluted
1:25 in blocking buffer) for three days at 4uC, washed overnight
with the same blocking buffer and finally incubated with goat anti-
rabbit IgG conjugated to FITC (Sigma, Canada) for another three
days at 4uC (dilution 1:300). If used as a counterstain, 200 mg/ml
TRITC-labelled phalloidin was added during the last two days
of incubation. The samples were mounted using anti-quench
mounting medium (Sigma, Canada) and examined with a BIO-
RAD RADIANCE 2100 confocal laser scanning microscope
(CLSM) equipped with a Nikon E800 fluorescence microscope for
confocal image acquisition and the LASERSHARP 2000 software
package. As negative controls, we used preimmune serum, omitted
the primary antibody and used primary antibody that was pre-
adsorbed with 0.5 mg/ml of pooled peptide antigens (0.25 mg of
each peptide).
Measurements of motor activity
3-day old in vitro transformed schistosomula were placed in
individual wells of a 24-well plate (30–40 animals/well) in 300 mlo f
OPTI-MEM+10% dialyzed serum. Following an adaptation period
of 15 min at room temperature, test substances were added at a final
concentration of 100 mM or as indicated. Animals were monitored
5 min after drug addition by placing the 24-well plate on a
compound microscope (Nikon, SMZ1500) equipped with a digital
video camera (QICAM Fast 1394, mono 12 bit, Qimaging) and
SimplePCI version 5.2 (Compix Inc.) for image acquisition. Images
were obtained at a rate of <3 frames/s for a period of 1 minute and
the data were analyzed with ImageJ software (version 1.41, NIH,
USA). Cultured schistosomula display complex motor behaviours
that are dominated by repeated changes in length, both shortening
andelongation.Toquantifythistypeofmovement,weusedthe‘‘Fit-
Ellipse’’ command of ImageJ to draw best-fit ellipses of individual
G Protein-Coupled Receptors of Schistosomes
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obtained by measuring the principal (‘‘major’’) axis of each ellipse,
using calibrated units (mm), and the frequency of length changes
during the observation period was calculated. Any change
representing .10% of body length, whether an increase or decrease,
was included in the calculation; changes #10% were disregarded.
Between12–15animalsweremonitoredperwellandtheexperiment
was repeated a minimum of 3 times. To monitor for possible drug
induced toxicity, viability tests were performed routinely using the
methylene blue dye exclusion assay described by Gold [32].
Bioinformatics analyses
Homology searches were performed by BLAST analyses
(tBLASTn or BLASTp) of the S. mansoni Genome Database (S.
mansoni GeneDB; www.genedb.org/genedb/smansoni/) [13], the
S. japonicum Transcriptome and Proteome Database (SjTPdb) [33],
the most current genome annotations of the planarians, Schmidtea
mediterranea (SmedGD version 1.3.14) [34] and Macrostomum lignano
(www.macgenome.org/index.html) and the general database
available at the National Center for Biotechnology Information
(NCBI). Sequences showing significant homology with SmGPR-3
were aligned with ClustalW and inspected manually for the
presence of conserved Class A (rhodopsin-like) GPCR motifs [23].
Phylogenetic trees were generated with MEGA4 [35], using two
different methods, neighbour-joining and Unweighted Pair Group
Method with Arithmetic mean (UPGMA) with similar results. The
trees were tested by bootstrap analysis with 1,000 replicates.
Predictions of transmembrane (TM) regions were made using the
TMpred server (http://www.ch.embnet.org) and by comparison
with the crystal structure of the human b2 adrenergic GPCR [36].
To facilitate identification, S. mansoni sequences are described
using both their S. mansoni GeneDB designation [13] and the
corresponding GenBank accession numbers. S. mediterranea se-
quences are identified by their SmedGD designation [34]. All
other sequences are identified by their GenBank accession
numbers. GPCR residues located within TM regions are described
according to the system of Ballesteros and Weinstein [37]. Each
amino acid within a TM region is identified by the TM number
(1–7) followed by the position in the TM helix relative to an
invariant reference residue, which is arbitrarily assigned the
number 50. Residue D
3.32, for example, is located in TM3, 18
residues upstream of the invariant reference residue. Amino acids
of relevance to this study are as follows (corresponding residue of
SmGPR-3): R
2.64 (Arg96), D
3.32 (Asp117), S
5.42 (Ser198), S
5.43
(Ser199), T
7.39 (Thr462) and Y
7.43 (Tyr466).
SmGPR-3 modeling and ligand docking
A theoretical model of SmGPR-3 was built with Accelrys
Discovery Studio (DS). Prior to generating the model, SmGPR-3
was aligned with the sequences of GPCR crystal structures
available in the general protein database (PDB) (Accession
numbers: 2rh1, 3eml, 1u19, 2vt4, 2z73) and the b-2 adrenergic
receptor (2hr1) was selected as the best template based on
similarity scores. The sequence alignment was inspected to ensure
that the positions of conserved residues in the structural template
were properly aligned with those of SmGPR-3, including the
reference residues designated at position 50 of each helix [37] and
conserved motifs, such as the DRY peptide at the end of TM3 and
the NPxxY motif of TM7. Subsequent preparation of the template
and construction of the model were performed with DS using
default parameters. The first stretch of 28 amino acid residues
corresponding to the extracellular N-terminal end was not
constructed due to lack of structural information. In addition,
we note that the b-2 adrenergic template is a chimeric receptor in
which the region corresponding to the third intracellular loop (il3)
was replaced with the sequence of T4 lysozyme [36]. Therefore
the il3 of SmGPR-3 (positions 224–417) could not be aligned and
was omitted from the model. Energy minimization was performed
using the CHARMm forcefield in DS. The conserved disulfide
linkage that occurs between the beginning of TM3 and extra-
cellular loop 2 (Cys110 and Cys186 in SmGPR-3) was constrained
during optimization of the model. The energy-minimized model
was subsequently verified by means of a Ramachandran plot
analysis and the PROFILES-3D evaluation method available in
DS. The quality score obtained with PROFILES-3D was within
acceptable range and the Ramachandran plot analysis showed
94.8% of the residues occurring in favourable regions of the plot,
suggesting the model was reliable. Superimposition of the model
with the b-2 adrenergic receptor template showed a backbone (Ca)
root-mean-square-deviation (RMSD) of 0.83 A ˚ and the overall
protein RMSD was 1.38 A ˚. For ligand-docking, the structure of
the ligand (dopamine or epinine) was generated with the molecular
builder panel available in the software and was energy-minimized,
as recommended. Next, we used DS to search for potential
binding cavities. Six potential sites were identified, of which only
one was located in the correct region based on the position of the
binding pocket in the structural template. The ligand was
subsequently docked onto this site of the SmGPR-3 model with
CDOCKER. Each ligand was docked in multiple conformational
states and orientations, which resulted in 240 different ligand poses
for dopamine and 290 for epinine. These were examined and
evaluated using the CHARMm scoring method of CDOCKER to
identify potential binding residues for each ligand.
Other methods
Protein content was measured with a Lowry assay (BioRad).
Indirect ELISA was performed in 96-well plates coated with
individual or pooled SmGPR-3 peptides (50–500 ng/well) and
incubated with a serial dilution of rabbit anti-SmGPR-3 antiserum
or preimmune serum (1:30,000–1:100), followed by incubation
with a horseradish peroxidase (HRP)-labeled secondary antibody
(goat anti-rabbit IgG, 1:2,000). Quantitative PCR (qPCR) was
performed as described previously [15,52] using the Platinum
SYBR Green qPCR SuperMix-UDG kit (Invitrogen) and a Rotor-
Gene RG3000 (Corbett Research) real-time PCR cycler. Statis-
tical comparisons were done with Student t-tests or a one-way
ANOVA, followed by a Tukey pairwise comparison. P#0.05 was
considered statistically significant.
Results
SmGPR-3 belongs to a new clade of schistosome BA-like
receptors
Predicted S. mansoni BA-like receptors [13] were aligned with
BA receptors from other species, including other flatworms for
which genomic data are available (S. japonicum, Dugesia japonica and
S. mediterranea) and both vertebrate and invertebrate representatives
of dopaminergic, serotonergic, adrenergic, histaminergic, tyra-
mine/octopamine and structurally related cholinergic muscarinic
(mACh) receptors. A phylogenetic tree of the alignment (Fig. 1)
shows a subset of schistosome GPCRs (SmGPR) that are derived
from a common node and constitute a separate clade within the
tree. Included in this clade are seven S. mansoni sequences and two
homologues from S. japonicum but no sequences from any of the
other species examined, including the free-living planarians. We
have previously described two members of this new clade,
SmGPR-1 (formerly SmGPCR; AAF21638; Smp_043260;) and
SmGPR-2 (GQ397114; Smp_043340) [15,25–27]. In the present
G Protein-Coupled Receptors of Schistosomes
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mansoni by RT-PCR. The cDNA was verified by DNA sequencing
(Accession # GQ259333) and was found to be identical to the
corresponding genomic prediction available at the S. mansoni
GeneDB (Smp_043290). SmGPR-3 has 497 amino acids and a
predicted MW of 58.4 kDa.
NCBI BLASTp analyses confirmed the identity of SmGPR-3 as a
member of the BA receptor family. According to pairwise alignment
analyses, the most closely related sequences are those of the SmGPR
clade including (% homology): SmGPR-1 (Smp_043260, 53.4%),
Smp_043300 (47.4%), SmGPR-2 (Smp_043340, 46.9%),
Smp_043270 (45.5%), Smp145520 (40.4%) and the S. japonicum
receptor FN328430 (46.1%). SmGPR-3 is also related to other
schistosome BA receptors (non-SmGPRs), as well as BA receptors
from other organisms but the level of homology is generally lower
(,40%). Further analysis of the SmGPR-3 protein sequence
detected all the hallmark features of Class A (rhodopsin-like) GPCRs
(Fig. 2). Aside from having the expected 7-TM topology, SmGPR-3
carries the signature DRY motif at the intracellular boundary of
TM3, the NPxxY motif of TM7 and all the conserved reference
residues at position #50 of each TM helix [37]. We also identified
several residues that have been implicated in BA binding and
receptor activation, notably the aromatic cluster FxxCWxPFF of
TM6 and a highly conserved aspartate at position 3.32 of TM3
(D
3.32/Asp117), which is considered to be one of the core binding
sites in BA GPCRs [23,36,38,39]. The presence of D
3.32 marks an
important difference between SmGPR-3 and other members of this
clade. The schistosome SmGPRs are unusual in that they carry an
asparagine substitution at this position [15]. SmGPR-3 is the only
receptor in this group where the aspartate D
3.32 is conserved.
SmGPR-3 is a dopamine/catecholamine receptor
Functional expression assays were performed in yeast. Prelim-
inary experiments failed to detect receptor expression in
mammalian cells (data not shown) and therefore we used yeast
as a heterologous expression system throughout the study. The
full-length SmGPR-3 cDNA was ligated to the Cp4258 vector
and the recombinant plasmid was transformed into Saccharomyces
cerevisae to test for receptor activity. We used a genetically modified
S. cerevisae strain that is designed for GPCR activity assays [29].
The yeast is auxotrophic for histidine and expresses a HIS3
reporter gene under the control of the FUS1 promoter. Activation
of a recombinant GPCR in this system increases expression of the
HIS3 reporter via the yeast’s endogenous pheromone response,
which in turn allows the cells to grow in selective histidine-deficient
medium. Thus receptor activity can be quantified based on
measurements of yeast growth in the selective medium, using a
fluorometric Alamar Blue assay. Cells transformed with either
Figure 1. Dendogram analysis of biogenic amine (BA) G protein-coupled receptors (GPCR). A rooted phylogenetic tree was constructed
from a ClustalW sequence alignment of vertebrate and invertebrate BA receptors, using MEGA 4 [35]. Included in the alignment are 15 predicted
Schistosoma mansoni and S. japonicum BA GPCR sequences, of which nine clustered together into a separate clade (SmGPR). The receptor described
in this paper, SmGPR-3 is identified by an open square (%). Other S. mansoni receptors are marked with solid squares (&) and S. japonicum receptors
are marked with solid triangles (m). Sequences are identified by their accession numbers and the species names are abbreviated as follows: A.e.
(Aedes aegypti), A.i. (Agrotis ipsilon), A.m. (Apis mellifera), B.m. (Bombyx mori), B.t. (Bos taurus), C.e. (Caenorhabditis elegans), C.f. (Canis familiaris), C.p.
(Cavia porcellus), D.m. (Drosophila melanogaster), D.j. (Dugesia japonica), D.r. (Danio rerio), H.s. (Homo sapiens), H.v. (Heliothis virescens), M.b. (Mamestra
brassicae), M.m. (Mus musculus), M.mul. (Macaca mulatta), P.a. (Periplaneta americana), P.x. (Papilio xuthus), R.n. (Rattus norvegicus), S.j. (S. japonicum),
S.med. (Schmidtea mediterranea), S.l. (Spodoptera littoralis) and S.s. (Sus scrofa). Predicted S. mansoni coding sequences are identified by their ‘‘Smp’’
designation obtained from the S. mansoni Genome database (S. mansoni GeneDB) and the corresponding GenBank Accession number. H1–H4,
histamine type 1–4 receptors; D1–D5, dopamine type 1–5 receptors; A, adrenergic receptors; 5HT, serotonin (5-hydroxytryptamine) receptors; mACh,
muscarinic acetylcholine receptors; OA/TA, octopamine/tyramine receptors.
doi:10.1371/journal.pntd.0001523.g001
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all different biogenic amines, each at 2610
24 M (Fig. 3A). The
results obtained from five to six individual clones showed that
SmGPR-3 was selectively activated by dopamine and its naturally
occurring metabolite epinine (deoxyepinephrine). Other catechol-
amines, including noradrenaline, adrenaline and the adrenaline
metabolite, metanephrine (not shown) also stimulated SmGPR-3
activity but not to the same extent as dopamine or epinine. The
receptor exhibited partial constitutive activity in the absence of
agonist but there was further activation in the presence of
catecholamines, whereas other biogenic amines had no significant
effect relative to the no drug control. Experiments were repeated
with different concentrations of dopamine or epinine and their
responses were shown to be dose-dependent. The half maximal
effective concentration (EC50) for dopamine and epinine activation
in the yeast expression system are 3.1610
25 M and
2.85610
25 M, respectively (Fig. 3B).
SmGPR-3 has atypical pharmacology
Next we examined the effects of classical (mammalian)
dopaminergic and other BA antagonists on the activity of
SmGPR-3. Drugs were tested initially at a single concentration
of 100 mM (10 mM in the case of flupenthixol) in the presence of
100 mM DA (Fig. 4A). The drug effects revealed an unusual
pharmacological profile, which did not resemble any of the
dopaminergic or adrenergic receptors of mammals. The most
surprising observation was that spiperone, a mammalian D2
antagonist enhanced the activity of SmGPR-3 nearly 2-fold, thus
behaving more as an agonist than a receptor blocker. Propranolol,
a b-adrenoceptor antagonist had no effect on this receptor, while
the remaining drugs showed various degrees of inhibition. Those
drugs that produced significant inhibition (.50%) in the initial
screen were subsequently tested at different concentrations to
obtain dose response curves (Fig. 4B–F). The half-maximal
inhibitory concentrations (IC50) for these drugs were as follows:
Haloperidol, 1.4610
26 M; Flupenthixol, 3.9610
26 M; Prometh-
azine, 2.8610
25 M; Mianserin, 4.5610
25 M; Clozapine
.10
24 M. Based on this analysis, the most effective antagonists
of SmGPR-3 were haloperidol and flupenthixol, two classical DA
antagonists, followed by promethazine, an antihistaminic drug not
known to interact with dopaminergic receptors. Mianserin, (mixed
adrenergic/5HT antagonist) and cyproheptadine, (mixed hista-
mine/5-HT antagonist) both produced significant inhibition of
<70% at the highest concentration tested. Finally the remaining
Figure 2. Sequence alignment of dopaminergic G protein-coupled receptors with Schistosoma mansoni SmGPR receptors. A ClustalW
alignment was performed using representative examples of vertebrate dopaminergic GPCRs (D1–D5), the S. mansoni dopamine D2-like receptor
(SmD2) and several members of the SmGPR clade. SmGPR sequences are boxed (horizontal box) and SmGPR-3 is marked by an arrow. Receptor
sequences are identified by their accession numbers (brackets). The positions of the predicted seven transmembrane domains are marked by
horizontal lines and the invariant residue in each TM segment [37] is identified by an asterisk (*) Other conserved residues of functional relevance are
marked by circles (N) and conserved motifs are boxed (vertical boxes). Residues discussed in this study, R
2.64 (Arg96), D
3.32 (Asp117), S
5.42 (Ser198),
T
7.39 (Thr462) and Y
7.43 (Tyr466) are identified by vertical arrows.
doi:10.1371/journal.pntd.0001523.g002
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including clozapine, a classical dopamine antagonist. Because the
assay is based on cell growth, we questioned whether the strong
inhibition induced by promethazine, flupenthixol and haloperidol
were due to drug-induced toxicity leading to cell death. To test this
possibility, we repeated the assay in medium supplemented with
histidine (100 mM), which enables cell growth irrespective of
receptor activation. The results showed normal or nearly normal
growth in the drug-treated cells in the presence of histidine,
indicating that the inhibitory effect of the drug was receptor-
mediated and not the product of generalized toxicity (Fig. 4A).
Immunolocalization of SmGPR-3
To investigate the tissue localization of SmGPR-3 we obtained a
specific antibody that targets two unique peptides of the receptor.
The antibody was affinity-purified and verified first by ELISA. To
test if the antibody could recognize the native receptor, we
immunoprecipitated (IP) SmGPR-3 from solubilized S. mansoni
membranes, using covalently-coupled anti-SmGPR-3 antibody
beads and then probed the IP eluate by western blotting with
affinity-purified anti-SmGPR-3 antibody. The results (Supplemen-
tal Fig. S1) detected a single major band of about 60 kDa, which is
consistent with the expected size of SmGPR-3. The negative
controls were similarly immunoprecipitated with the same
antibody beads but were probed either with peptide-preadsorbed
antibody or preimmune serum. The results show much diminished
or no immunoreactivity in the negative controls, suggesting the
antibody recognizes SmGPR-3 specifically. For the in situ
immunolocalization studies, larval and adult stages of S. mansoni
were probed with affinity-purified anti-SmGPR-3, followed by a
FITC-labelled secondary antibody. Some animals were also
treated with TRITC-conjugated phalloidin to label cytoskeletal
elements and muscle [31]. The results show strong SmGPR-3
green fluorescence in the nervous system of both cercaria and
adult S. mansoni. In cercaria we see immunoreactivity primarily in
the CNS along the main longitudinal nerve cords and transverse
commissures (Fig. 5). The pattern of labelling is similar to that of
dopamine itself, which localizes to the same regions of the CNS in
cercaria of both S. mansoni and S. japonicum [14]. Adult worms have
high levels of SmGPR-3 immunoreactivity in the cerebral ganglia
and major longitudinal nerve cords. This was observed in
adult males (Fig. 6A) as well as female worms (not shown). The
peripheral nervous system (PNS) is also rich in SmGPR-3.
Immunoreactivity can be seen in the innervation of the caecum
(Fig. 6B) and the peripheral plexuses and fibers innervating the
parasite musculature (Fig. 6C), both circular and longitudinal
muscles (Fig. 6D, E). There is no apparent co-localization of
SmGPR-3 labelling (green) and the somatic muscles (red) that
were counterstained with TRITC-conjugated phalloidin, suggest-
ing the receptor is probably associated with the innervation of the
musculature rather than the muscle itself. Other regions of
significant labelling include the peripheral plexus of the ventral
sucker (Fig. 6F) and, in male worms, the tubercles and the
innervation of the testes (Fig. 6G–I). No significant fluorescence
was observed in any of the negative controls tested, including
worms probed with pre-immune serum, secondary antibody only
and antibody that was pre-adsorbed with the peptide antigens.
In vitro motility assays
The prevalence of SmGPR-3 in the peripheral innervation of
the somatic muscles suggests this receptor could be involved in the
control of motor activity. To explore this possibility we tested the
effects of several SmGPR-3 agonists and antagonists on the motor
activity of intact schistosomula in culture. The goal of these studies
was to determine whether substances that interact with the
recombinant receptor in vitro also influence worm movement, which
could suggest involvement of SmGPR-3 inmotor control. Weused a
larvalstage(schistosomula)insteadofadultwormsbecausethelarvae
are better suited for quantitative measurements of movement. A
preliminary analysis by confocal immunofluorescence detected
expression of SmGPR-3 in the nervous system of the schistosomula
(data not shown). We also determined that SmGPR-3 could be
amplified from schistosomula oligo-dT reverse-transcribed cDNA
using both end-point and real-time quantitative PCR (Supplemental
Fig. S2), thus confirming that the receptor is expressed in this larval
stage. Measuring schistosome movement is challenging because the
worms do not travel (i.e. swim) in culture. To quantitate motor
activity, we monitored individual schistosomula in the presence and
absence of test substances, using a microscope equipped with a video
camera and imaging software. Approximately 180 consecutive
frameswererecorded for eachanimalover 1 min ofobservation and
the approximate length of the animal ineachframe was measured in
calibrated units (mm). An individual recording of a control
(untreated) animal is shown in Fig. 7A (top panel). When cultured
in vitro, schistosomula exhibit repeated cycles of elongation and
contraction, which cause the animal to increase or decrease its body
Figure 3. Functional expression of the Schistosoma mansoni
SmGPR-3 receptor in yeast. (A) The full-length SmGPR-3 cDNA was
expressed in Saccharomyces cerevisae strain YEX108 and grown in
selective leu/histidine-deficient (leu
2/his
2) medium containing
2610
24 M of each biogenic amine or vehicle (no drug control, ND).
Yeast cells transformed with empty plasmid were used as a negative
control (mock). Receptor activation was quantified from measurements
of yeast growth in relative fluorescence units (RFU), using an Alamar
blue fluorescence assay. The results are the means 6 S.E.M. of 5–6
independent clones, each assayed in triplicate. The following biogenic
amines were tested: adrenaline (A), noradrenaline (NA), dopamine (DA),
epinine (EPN), serotonin (5-hydroxytryptamine, 5HT), octopamine (OA),
tyramine (TA) and histamine (HA). (B) Functional assays were repeated
with the same SmGPR-3-expressing yeast strain and variable concen-
trations of DA (g) or EPN (%). The mock control was tested with DA (N).
EC50 values for DA and EPN are 3.10610
25 M and 2.85610
25 M,
respectively. The data are the means 6 S.E.M. of two experiments, each
in triplicate.
doi:10.1371/journal.pntd.0001523.g003
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catecholamines significantly altered this behaviour. The addition of
dopamine or epinine, each at a concentration of 100 mMc a u s e d
marked inhibition of motor activity. Dopamine decreased both the
amplitude and frequency of contractions and epinine caused virtual
paralysis in all animals tested. To quantify the level of motor activity,
we repeated experiments at different concentrations of each amine
and then calculated the frequency of length changes, both decrease
and increase for each individual animal during the 1 min of
observation. Mean values were obtained from the average of 12–15
animals/experiment and each experiment was repeated a minimum
of 3 times. The data (Fig. 7B) confirmed the inhibition caused by
dopamine and epinine and showed that the effect was dose-
dependent. In both cases, significant inhibition was observed at
concentrations equal to or .10 mM.
The study was subsequently expanded to test other drugs
that normally interact with BA receptors and were shown to have
activity towards recombinant SmGPR-3 in the yeast assay.
Substances were tested at 50 mM (flupenthixol, promethazine,
epinine, dopamine) or 500 mM (adrenaline, metanephrine, halo-
peridol). With the exception of haloperidol, which had no
significant motor effects, all the other substances produced
significant changes (P,0.05) in motor activity compared to the
untreated larvae (Fig. 7C). However the results do not show a
correlation between the phenotypic effects of these drugs and those
seen in vitro with the recombinant receptor. Adrenaline and its
methylated derivative, metanephrine have weak agonist activity
towards SmGPR-3 in the yeast assay, yet they were found to have
opposite effects on larval motility. Adrenaline produced the same
decrease in motility as dopamine and epinine, whereas meta-
nephrine caused marked hyperactivation, increasing the frequency
of body wall movements <3-fold. Among the antagonists of
SmGPR-3, haloperidol had no effect but flupenthixol and
promethazine both caused a significant decrease in motor activity.
Drug-treated animals were routinely assayed for viability, using the
methylene blue dye exclusion assay described by Gold [32]. There
were no measurable effects on viability at the drug concentrations
tested, though we cannot rule out some degree of drug-induced
toxicity that would not be detected by this assay.
SmGPR-3 homology modeling and ligand docking
Studies of mammalian BA receptors have localized the agonist
binding pocket to a crevice formed by residues near the extra-
cellular side of the TM helices, particularly TM3, 5, 6 and 7
[23,36,38–43]. Several ligand-interacting residues have been
identified within this pocket. Of particular importance in cate-
cholamine (dopamine, adrenergic) receptors is the aforementioned
aspartate of TM3 (D
3.32), which anchors the protonated amino
group of the ligand, and three closely positioned serines in TM 5
(S
5.42,S
5.43,S
5.46), which interact with the hydroxyl groups on the
Figure 4. Antagonist effects on SmGPR-3 activity. (A) Yeast YEX108 auxotrophic his strain expressing SmGPR-3 was incubated with agonist (DA,
100 mM) and test antagonist or vehicle. Antagonists were tested at 100 mM except for flupenthixol, which was used at 10 mM. The data were
normalized relative to the control sample that contained 100 mM DA but no antagonist. To test for drug induced toxicity, assays were repeated in the
presence of 100 mM test antagonist in histidine-supplemented (his+) medium, which enables the cell to grow irrespective of receptor activation (His
+ve control; see text for details). Abbreviations are as follows: SPIP, spiperone; PROP, propanolol; CLZP, clozapine; BUSP, buspirone; MINS, mianserin;
CPRH, cyproheptadine; FLPX, flupenthixol; PRMZ, promethazine; HLRD, haloperidol. B–F. Dose-dependent inhibiton by haloperidol (IC50=1.4 mM),
flupenthixol (IC50=3.9 mM), promethazine (IC50=28.0 mM), mianserin (IC50=45.0 mM) clozapine (IC50.100 mM). The error bars are the means 6 SEM
for 3–4 experiments and at least 2 clones (in triplicates).
doi:10.1371/journal.pntd.0001523.g004
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SmGPR-3 (D
3.32,S
5.42,S
5.43) and therefore we questioned
whether they might be involved in the interaction with dopamine.
A homology model of SmGPR-3 was obtained from a structural
alignment with the b2-adrenergic receptor (2rh1) and used for
docking simulations. The hypothetical structure shows the typical
topology of a Class A GPCR with 7 TM helices and one additional
short helix (helix 8) at the C-terminal end that runs parallel to the
membrane (Fig. 8A). Starting with this structure, we searched for
potential binding cavities, using the site finder command in
Discovery Studio. The analysis identified a possible site, which was
located in the expected region of the receptor and included the
canonical D
3.32 of TM3 (residue Asp117). The dopamine structure
was docked virtually onto this site and 240 docked ligand poses
were examined and scored to search for the most favourable
binding interactions. We identified approximately 20 residues
located within 5 A ˚ of the docked ligand, which are predicted to
form the binding pocket of the receptor (Table S1). Among these
residues there are five amino acids showing direct interactions with
dopamine (Arg96/R
2.64, Asp117/D
3.32, Ser198/S
5.42, Thr462/
T
7.39 and Tyr466/Y
7.43) (Fig. 8A, B). The protonated amino
group of dopamine is anchored to Asp117/D
3.32 of TM3, as
expected, and also forms additional H-bond interactions with
Thr462/T
7.39 and Tyr466/Y
7.43of TM7. As for the catechol ring
of dopamine, we observed more that one set of interactions
depending on the orientation of the ligand. The most favourable
orientation (highest docking scores) had the catechol ring
interacting with Arg96/R
2.64 of TM2 (Fig. 8C, yellow). Dopamine
could also be docked in a different orientation where the catechol
ring was pointed towards TM5 and interacted with one of the
conserved serines of TM5, Ser198/S
5.42 (Fig. 8C, magenta) but
the docking scores were lower and we did not see interactions with
the other conserved serine of TM5 (Ser199/S
5.43). About 85% of
the docked poses examined had interactions with Arg96/R
2.64 of
TM2 instead of Ser198/S
5.42 (Fig. 8D). Since SmGPR-3 is as
responsive to epinine as it is to dopamine, we repeated the docking
simulation using epinine as the ligand. An overlay of all the
potential docked poses shows that epinine binds to the same pocket
as dopamine and interacts with the same core residues (Fig. 8E).
Like dopamine, the most favourable epinine interactions involved
residues of TM3 (Asp117/D
3.32), TM2 (Arg96/R
2.64) and TM7
(Thr462/T
7.39 and Tyr466/Y
7.43). We also observed less favour-
able interactions between the catechol ring of epinine and TM5,
similar to dopamine, except in this case interactions occurred with
both conserved serines, Ser198/S
5.42 and Ser199/S
5.43.
Discussion
The S. mansoni genome encodes 16 GPCR-like sequences that
share significant homology with aminergic receptors from other
species [13]. A comparative bioinformatics analysis of these
putative S. mansoni BA receptors with homologues of vertebrate
and invertebrate origins enabled us to identify a new clade, the
SmGPRs, which contains approximately half of all S. mansoni
aminergic receptors and at least another two homologues of S.
japonicum [15]. SmGPRs are easily recognized as Class A GPCRs
due to their heptahelical organization, short N-terminus and the
presence of signature motifs such as the DRY peptide (near TM3),
FxxCWxxFF (TM6) and NPxxY (TM7) among others. Neverthe-
less, these receptors are considered novel; they are clearly more
related to each other than they are to other BA receptors in the
database, including other schistosome BA receptors. The dendo-
gram analysis suggests that the SmGPRs diverged from a common
ancestor early in evolution, probably through a series of gene
duplications that gave rise first to the SmGPR-1/SmGPR-3
branch and subsequently the remaining sequences. We note that
the SmGPR sequences grouped within this clade are all located in
relatively close proximity to each other in the S. mansoni genome
(Smp_scaff000103) [13], which is consistent with a mechanism of
gene duplication. A distinctive feature of the SmGPRs is the
absence of residue D
3.32, which is replaced with an asparagine in
all of these sequences except for SmGPR-3. As mentioned earlier,
D
3.32 is highly conserved in BA receptors [22,36,38,39] and
therefore the asparagine substitution marks a significant departure
from current models of receptor structure. Thus far SmGPRs have
been found only in S. mansoni and S. japonicum. We checked all the
available planarian genomes as well as the general database at
NCBI and found no other sequences that aligned within this clade.
As more genomes become available, it will be of interest to
determine if SmGPRs are present in other parasitic flatworms or if
they are unique to schistosomes.
The functional expression analysis of SmGPR-3 was conducted
in yeast cells. Yeast provides a robust expression system for
recombinant, hard to express proteins. SmGPR-3 could not be
expressed in mammalian cells (not shown) but it produced a
functional receptor when expressed in the budding yeast S.
cerevisiae. SmGPR-3 is the third member of this clade to be cloned
and characterized. The first two (SmGPR-1 and -2) were found to
be selectively activated by histamine when expressed in vitro
[15,25]. Given the structural similarity among these receptors, we
questioned whether SmGPR-3 might also be responsive to
histamine. However the activity assays revealed that SmGPR-3
was preferentially activated by catecholamines. The strongest
response was obtained with dopamine and its methylated
derivative, epinine, but the receptor also recognized noradrenaline
and adrenaline, suggesting broad specificity for catechol deriva-
tives. When tested against classical dopaminergic and other BA
antagonists, SmGPR-3 exhibited a mixed pharmacological profile
that did not conform to any known mammalian receptor. The
Figure 5. Immunolocalization of SmGPR-3 in larval Schistosoma
mansoni. S. mansoni cercaria were probed with affinity purified anti-
SmGPR-3 antibody, followed by fluorescein isothiocyanate (FITC)-
labelled secondary antibody. (A) Immunoreactivity (green) can be seen
along the major longitudinal nerve cords (solid arrowheads) and in
transverse commissures (open arrowhead), including the posterior
transverse commissure near the base of the tail (open arrow). (B) No
significant immunoreactivity was observed in negative controls probed
with anti-SmGPR-3 antibody that was pre-adsorbed with peptide
antigens or (C) controls probed with secondary antibody only. (*) non-
specific labelling.
doi:10.1371/journal.pntd.0001523.g005
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antagonists (haloperidol, flupenthixol), an anti-histaminic drug
(promethazine) and a relatively nonselective inhibitor (cyprohep-
tadine) that normally targets serotonin and histaminergic recep-
tors. In contrast, anti-dopaminergics such as clozapine and
spiperone either had little inhibitory effect or exhibited agonist
activity. Interestingly, we noted that two of the most potent
inhibitors of SmGPR-3, promethazine and flupenthixol, are also
the most potent inhibitors of SmGPR-2 [15], suggesting that
SmGPRs may have common pharmacological properties, even if
the amine ligands are different.
To explore the role of SmGPR-3 in the bloodfluke, we
produced a specific polyclonal antibody and then examined the
tissue distribution of the receptor in different developmental stages
of the parasite by confocal immunofluorescence. The results show
that this receptor is predominantly neuronal and is expressed in
the nervous system of both larvae (cercaria) and adult worms. The
distribution of SmGPR-3 immunoreactivity in cercaria closely
parallels that of catecholamine-containing neurons, which were
previously described in S. mansoni and S. japonicum by biochemical
methods [14]. In cercaria these neurons localize in part to the
major longitudinal nerve cords and the posterior transverse
commissure, sites that are also enriched in SmGPR-3. SmGPR-
3 is probably activated by dopamine released from these centrally
located neurons and mediates inter-neuronal dopamine signalling
within the cercarial CNS. In the adults, SmGPR-3 is more
widespread and localizes both to the CNS and elements of the
PNS, suggesting a greater diversity of activities. As in the larvae,
Figure 6. Immunolocalization of SmGPR-3 in adult Schistosoma mansoni. Adult male worms were treated with affinity-purified anti-SmGPR-3
polyclonal IgG, followed by fluorescein isothiocyanate (FITC)-labelled secondary antibody (green). Animals were counterstained with
tetramethylrhodamine B isothiocyanate (TRITC)-labelled phalloidin (red) to visualize the musculature of the body wall and digestive tract. (A)
Strong SmGPR-3 immunoreactivity is visible in the region of the cerebral ganglia (cg) and along the main longitudinal nerve cords (lnc) of the CNS. (B)
Green fluorescence can also be seen in peripheral nerve fibers innervating the caecum (open arrows). (C) Near the surface SmGPR-3 is strongly
expressed in the peripheral innervation of the body wall muscles and the tegument. Numerous immunoreactive nerve fibers (open arrows), some
varicose in appearance, are visible throughout this region. At higher magnification (D, E) we see SmGPR-3–expressing nerve fibers (open arrows) and
cell bodies (solid arrowhead) innervating the body wall muscles, both circular muscle (cm) and typically spindle-shaped longitudinal muscle fibers
(lm). SmGPR-3 immunoreactivity is seen in the tubercles of male worms (D, solid arrow), where it is probably associated with sensory nerve endings.
(F) SmGPR-3 is expressed in the nerve plexus and small fibers of the ventral sucker. Extensive labelling of the submuscular nerve plexus can also be
seen in this specimen (solid arrows). (G, H) A male worm showing strong labelling of major nerve cords (solid arrows) and the reproductive tract,
including the testes (t) and associated nerves. (I) Fine SmGPR-3 immunoreactive nerve fibers (open arrows) innervate the testicular lobes of male
worms. lnc, longitudinal nerve cords; cg, cerebral ganglia; c, caecum; lm, longitudinal muscle; cm, circular muscle; vs, ventral sucker; t, testes; gc,
gynecophoral canal.
doi:10.1371/journal.pntd.0001523.g006
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longitudinal nerve cords and cerebral ganglia. In addition, the
adult worms express high levels of SmGPR-3 outside the CNS,
particularly in the smaller peripheral nerve fibers and plexuses that
supply the body wall muscles and the suckers among other tissues.
We do not know how this compares with the distribution of
dopamine neurons in the adults, which has yet to determined.
However there is evidence from other flatworms that dopamine
neurons are present both in the CNS and the peripheral
innervation of the somatic muscles, where dopamine is believed
to play an important role in motor control [16,18]. Our results
thus suggest that SmGPR-3 has important activities both within
and outside the CNS in adult worms. The prevalence of SmGPR-
3 in the nerve fibers of the circular muscles strongly implicates this
receptor in the control of muscle function and suggests this is one
of the mechanisms by which dopamine controls movement of the
worm.
The first evidence of dopaminergic activity in schistosomes dates
back to the 1970s, when researchers reported that addition of
dopamine caused a pronounced lengthening of the body in intact
adult worms [44,45]. Subsequent studies demonstrated that the
lengthening effect was due to relaxation of the body wall muscles
[21]. It was further suggested that dopamine had both direct and
indirect effects on the musculature, possibly by acting through
more than one receptor [21], though the molecular mechanisms
were unknown. Our continuing investigation of this system is
beginning to shed new light on these early observations. SmGPR-3
is the second dopamine receptor to be identified in S. mansoni. The
tissue distribution of the other receptor, named SmD2 is quite
different from that described here. SmD2 is absent in the CNS and
it is enriched in the body wall muscles [22]. Although SmGPR-3 is
also present in the body wall, it is associated with neuronal
elements rather than the muscle per se; we did not see any co-
labelling of SmGPR-3 with phalloidin, the counterstain that was
used to probe the muscle layers. Thus, we conclude that there are
at least two routes of dopaminergic motor control in S. mansoni
involving both direct and indirect mechanisms, as was hypothe-
sized in the earlier studies. One pathway is mediated by SmD2,
which is predicted to act directly on the musculature, whereas the
second is a more indirect neuronal pathway mediated by SmGPR-
3. The localization of SmGPR-3 suggests that the receptor
probably controls neuronal input to the body wall muscles,
most likely by modulating release and/or signalling activity of
another transmitter. This type of indirect activity is consistent with
the notion that BAs can function both as neuromodulators and
classical neurotransmitters. For example, in C. elegans dopamine
controls motor activity indirectly through centrally located
neurons that in turn modulate muscle function [46].
While it is well established that dopamine has inhibitory
neuromuscular effects in schistosomes [21], the outcome of these
effects on movement is unclear. Some early studies reported an
increase in the length of the body but no effect on motility [44]
whereas others reported both an increase in length and a decrease
in motor activity when adult worms were treated with dopamine
[45]. These studies were based on qualitative assessments of worm
movement and did not include larval stages of the parasite. We
have revisited this issue using a more quantitative imaging assay
and in vitro transformed schistosomula, which are best suited for
Figure 7. Effects of dopamine and related substances on schistosome motility. (A) In vitro transformed 3-day-old schistosomula were
incubated with test drug, dopamine (DA) or epinine (EPN), each at (10
24 M) or vehicle (CT, control). Animals were treated for 5 min at room
temperature, after which they were examined with a compound microscope equipped with a digital video camera and SimplePCI (Compix Inc.) for
image acquisition. Images were recorded for 1 minute (,3 frames/second) and an estimate of body length in mm was obtained for each animal in
every frame. Each tracing shown is of an individual animal and is representative of 12–15 larvae per experiment and 3–4 independent experiments
per treatment. (B) Experiments were repeated with various concentrations of test agonist in a range of 10
27 M–10
24 M, or in the absence of test
substance (CT, control). Images were recorded as above and body length was measured for each frame. Motility is defined as the frequency of length
changes (shortening and elongation) per minute of observation, as described in the Methods. The data are presented as the means and SEM of three
separate experiments each with 12–15 animals. (C) Schistosomula were treated with test substances at a single concentration or in the absence of
drug (CT, control) and motility was measured as above. Dopamine (DA), epinine (EPN), flupenthixol (FLPX), promethazine (PRMZ) were each tested at
50 mM. The remaining substances, adenaline (A), metanephrine (MTN) and haloperidol (HLRD) were tested at 500 mM. The data are the means and
SEM of three separate experiments each with 12–15 animals. * Significantly different from the no drug control at P,0.05.
doi:10.1371/journal.pntd.0001523.g007
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that dopamine has inhibitory motor effects in schistosomes;
dopamine-treated larvae were significantly less motile than the
controls. The inhibition was dose-dependent, starting at about
10 mM, and resulted in nearly complete paralysis at higher
concentrations. Similar effects were observed in larvae treated with
adrenaline and the dopamine metabolite, epinine, suggesting this
is a common response to catecholamines. The inhibitory effect of
dopamine described here is much stronger than that reported
earlier for adult worms [44,45] but, surprisingly, we did not see an
overall increase in body length, which was a predominant response
in the adults. This discrepancy could be due to differences in
experimental protocol or it could be a function of the different
developmental stages used in the studies, larvae versus adults. As
mentioned earlier, the distribution of SmGPR-3 is more
widespread in the adult worms than the larvae. SmGPR-3
localizes to the peripheral innervation of the somatic muscles in
the adults whereas in the larvae it is more restricted to the CNS. It
is possible the different dopamine-induced behaviours, paralysis
versus elongation, are due to developmental changes in the
expression patterns of these receptors.
Besides catecholamines, we repeated motility assays with a
variety of substances that were shown to interact with the reco-
mbinant SmGPR-3 in the yeast system. Given that exogenous
dopamine paralyzes the larvae, we had expected antagonists of this
receptor to cause hyperactivity but that was not observed. One of
the antagonists tested, haloperidol, caused a small increase in
motility but this was not statistically significant, whereas the other
two (flupenthixol and promethazine) had the opposite effect and
caused marked inhibition of movement at the concentrations
tested. A probable explanation for these results is that the drugs
are interacting with more than one receptor in the intact parasite,
Figure 8. Homology modeling of SmGPR-3 and ligand docking. (A) A homology model of SmGPR-3 with bound dopamine (DA) is shown. The
model was generated using the b-2 adrenergic receptor (PDB Accession # 2rh1) as a structural template, as described in the Methods. The positions
of the 7 predicted transmembrane (TM) helices and 3 extracellular loops (ECL) are marked. The additional intracellular helix at the C-terminal end
(helix 8) is also shown. Amino acid residues that are predicted to interact with dopamine include: Arg 96 (R
2.64), Asp117 (D
3.32), Thr462 (T
7.39) and
Tyr466 (Y
7.43). (B) Close-up of the predicted binding pocket showing the best docking pose of dopamine (DA) and the principal ligand binding
residues. (C) Two different docking poses of dopamine (DA) are shown. Note that the position of the catechol ring in the two conformations is
reversed. In the best scoring pose (yellow), the ring hydroxyl interacts with Arg96 (R
2.64) near the extracellular junction of TM2, whereas in the other
docking pose (magenta) the ring interacts with Ser198 (S
5.42) of TM5 instead. In both cases the protonated amino end of dopamine is anchored to
Asp117 (D
3.32) of TM3. An overlay of potential docking poses of dopamine (DA, panel D) and the structurally related ligand, epinine (EPN, panel E)
shows the majority of interactions occurring with TM2, 3 and 7 for both ligands. The core interacting residues are shown and predicted H-bonds are
marked by broken green lines.
doi:10.1371/journal.pntd.0001523.g008
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homologue, or others that have yet to be identified. The paralysis
caused by promethazine and flupenthixol could be due to
interactions with SmGPR-2, which is also strongly inhibited by
these drugs [15]. Another consideration is the possibility of general
(receptor-independent) toxicity effects. The drugs used in this
study did not affect parasite viability but we cannot rule out other,
more subtle effects that might have hindered motility and were not
detected in this study. One of the more unexpected results of this
survey was the effect of metanephrine on the larvae. Metanephrine
is structurally related to adrenaline but it had the opposite effect on
larval movement. Whereas adrenaline caused paralysis, the
metabolite caused very strong hyperactivity, more than doubling
the frequency of movement. Metanephrine was found to have
weak agonist activity towards SmGPR-3 in vitro (not shown); it
is possible that an excess of exogenous metanephrine is able to
compete with endogenous dopamine (or adrenaline) for this
receptor, thus decreasing endogenous signalling. Although the
mode of action remains unclear, the results nonetheless show that
catecholamine metabolites and other dopaminergic agents have
strong effects on larval motility. The challenge for future studies is
to determine which of the S. mansoni dopamine receptors, smGPR-
3, SmD2 or others is targeted by these drugs and to identify more
selective inhibitors that could be used to disrupt parasite
movement.
The strong effects of epinine and metanephrine on larval
motility raise interesting questions about the possible role of these
substances in the parasite. In mammals, epinine is a naturally
occurring but relatively minor by-product of DA metabolism. It is
produced from DA by the activity of phenylethanolamine N-
methyltransferase (PNMT) and can be further metabolized to
adrenaline, though this reaction rarely occurs in mammals [47].
Metanephrine is one of the major metabolites of adrenaline in
humans; it is synthesized through the action of catechol-O-methyl
transferase (COMT) and it is normally excreted in the urine.
Although they are considered to be inactive metabolites in higher
organisms, epinine and metanephrine are biologically active in
some protozoa and invertebrates. For instance, epinine replaces
noradrenaline as the major substrate for adrenaline biosynthesis in
the unicellular protozoan Tetrahymena pyriformi [48]. In the
cnidarian, sea pansy Renilla koellikeri, epinine, metanephrine and
another related metabolite, normetanephrine, are all present at
high levels and are believed to be neuroactive [49]. It is unknown
if these substances also occur in flatworms. We note, however, that
at least some of the enzymes required for endogenous biosynthesis
of these substances are present in schistosomes. The S. mansoni
genome encodes a putative O-methyltransferase (CAZ32787,
Smp_052470) that shares significant homology with COMTs
from other species. If these metabolites are produced by the
parasite, their interaction with SmGPR-3 and strong effects on
larval motility could prove to be biologically important.
In the absence of a crystal structure, which is lacking for all but
a few GPCRs, researchers often resort to homology models to
explore the structural organization of new receptors. We have
produced a homology model of SmGPR-3, using the human b2-
adrenergic receptor as a structural template, and then performed
virtual docking of dopamine onto the hypothetical structure. It has
been published that dopamine/adrenergic receptors bind their BA
ligands through the highly conserved D
3.32 in TM3 and through
one or more of three serines (S
5.42,S
5.43 and S
5.46) present in TM5
[23,36,39–43]. SmGPR-3 has the conserved D
3.32 of TM3 and
two of the serines (S
5.42 and S
5.43) in TM5 but S
5.46 is missing. We
questioned whether a different residue might substitute for the
missing serine or, given the novelty of the sequence, dopamine
could interact with different residues entirely. Our docking
simulation verified the interaction with D3.32 (Asp117) but
suggests that the serines of TM5 are unlikely to play a major
role in dopamine binding. Instead, we found potential binding
sites in TM2 and TM7. One of the more interesting findings of
this analysis is the predicted interaction with R
2.64 (Arg96) of
TM2. This arginine is not conserved in the mammalian dopamine
receptors and the cognate residue (alanine or hydrophobic) is not
known to be directly involved in dopamine binding. Another
surprising difference is the apparent absence of ligand interactions
with aromatic residues of TM6, which are conserved in SmGPR-3
(F
6.51,F
6.52) and would normally be expected to contribute to the
binding of the catechol moiety. These differences must be viewed
with caution, given the low sequence homology of SmGPR-3
compared to the template and the inevitable artefacts associated
with homology models. Nevertheless, the results identify poten-
tially important differences between the parasite and host
receptors that can now be tested by mutagenesis and functional
analyses. The predicted involvement of R
2.64 is particularly
noteworthy because of its location near the extracellular junction
of TM2. The TM2 junction is a major component of the
antagonist binding pocket in the human D3 receptor [40] and
therefore this region could be important for the function and
pharmacology of SmGPR-3. The fact that R
2.64 is not conserved
in the host (but is present in all the SmGPRs) further identifies this
region as a potential target for the development of selective
receptor blockers.
This study adds to a growing body of molecular evidence that
points to dopamine as a major neurotransmitter of the schistosome
nervous system. Besides SmGPR-3 and the previously described
SmD2 receptor [22], researchers have characterized a dopamine
biosynthetic enzyme in S. mansoni [50] and, more recently,
discovered a high-affinity dopamine transporter [51], which is
likely involved in the recycling/inactivation of the amine. The
broad distribution of SmGPR-3 reported here suggests a great
diversity of dopamine activities in this parasite, more than was
previously believed. Although we have focussed our attention on
neuromuscular and motor effects, it should be noted that SmGPR-
3 was also found in the innervation of the caecum, the tubercles
and, interestingly, the male reproductive system. Very little is
known about the neuronal control of reproduction in schisto-
somes. We have previously identified a glutamate receptor in the
female reproductive tract of S. mansoni [52] but, to our knowledge,
this is the first evidence of a neurotransmitter receptor expressed in
the male testes and it suggests a novel role for dopamine in this
system. The presence of SmGPR-3 in the male tubercles is also
noteworthy. Several neurotransmitters and neuronal proteins have
been identified in the tubercles of schistosomes, where they are
believed to be associated with sensory nerve endings [53–55].
SmGPR-3 expressed in these sites could play an important role in
chemosensory signalling, either as part of an endogenous pathway
or in response to exogenous (host-derived) catecholamines. More
research is needed to clarify the nature of these effects and to
elucidate the mode of action of dopamine in the parasites.
Supporting Information
Figure S1 Immunoprecipitation and western blot anal-
ysis of SmGPR-3. SmGPR-3 was immunoprecipitated (IP) from
a preparation of solubilized S. mansoni membranes, using a specific
anti-SmGPR-3 peptide antibody that was covalently coupled to
agarose beads. After washing, the bound proteins were eluted from
the antibody beads under acidic conditions and immunoblotted
(IB) with purified anti-SmGPR-3 antibody (duplicate samples),
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www.plosntds.org 13 February 2012 | Volume 6 | Issue 2 | e1523peptide-preadsorbed antibody or pre-immune serum. The sizes of
relevant protein standards are indicated.
(TIF)
Figure S2 Expression of SmGPR-3 in S. mansoni
schistosomula. (A) Quantitative PCR (qPCR) was performed
on oligo-dT reverse-transcribed cDNA from S. mansoni schisto-
somula. The larvae were obtained from cercaria by mechanical
transformation [27,28] and were tested at 3 days and 8 days post-
transformation with similar results. Real-time qPCR was per-
formed as described previously [15,52], using primers designed to
amplify a SmGPR-3 product of 243 bp (forward: 59-CCACTG-
GACAAATGATTGTATTG-39; reverse: 59-ACCATTCCATT-
GAAACATCCATTAC-39) or a 206 bp fragment of S. mansoni
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Accession
# M92359), which was used as a housekeeping gene control
(forward: 59-GTTGATCTGACATGTAGGTTAG-39; reverse:
59-ACTAATTTCACGAAGTTGTTG-39). The qPCR cycling
conditions were as follows: 53uC/30 s, 94uC/2 min followed by
50 cycles of 94uC/15 s, 53uC/30 s and 72uC/30 s. The data show
typical amplification curves for GAPDH and SmGPR-3 obtained
from a single experiment in duplicates. Average (6 SEM) Ct
values were determined from 3 separate experiments, each in
duplicate or triplicate: SmGPR-3, Ct=23.262.3; GAPDH,
Ct=19.562.0. (B) Conventional end-point RT-PCR was per-
formed with RNA obtained from 3 day-old schistosomula, using
PCR primers designed to amplify a 461 bp fragment of SmGPR-3
(positions 1–461). A band of the correct size was observed in
samples containing oligo-dT reverse-transcribed cDNA (lane 1)
but not a negative control that lacked reverse transcriptase (lane 3).
As a positive control, the PCR was repeated with the cloned
SmGPR-3 cDNA (pGEM-T/SmGPR-3 plasmid) as a template
and the same size band was observed (lane 2).
(TIF)
Table S1 Binding site residues interacting within 5 A ˚ of
the ligand.
(DOC)
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